glp 1 with cv benefit The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Stopping GLP-1s Increases Risk of

Unfortunately, this will mean that lower wage employees unable to afford the upfront cost will be less likely to obtain the benefits from GLP-1 medications

Limitations include that the data came from 1 health system in the US, most patients were white, and it was unknown why patients were prescribed this medication, although 93% were diabetic

Healthcare providers should remain attentive to patient-reported symptoms while recognizing that correlation does not necessarily indicate causation

Many patients report meaningful results within 4-6 weeks, making early affordability critical to sustained treatment engagement

Daily fat intake is associated with basolateral amygdala response to high-calorie food cues and appetite for high-calorie food

Among employers covering GLP-1 agonist drugs for weight loss, most firms view it as important or very important for employee satisfaction The meaningful shares of larger employers covering these medications for weight loss, notwithstanding their relatively high cost, underscores the importance many employers place on covering these medications for employees